Sample Collection for Ongoing Research and Product Evaluation Study

The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's molecular residual disease (MRD) testing across multiple cancer types. The study aims to assess the ability of Natera's assays to detect circulating tumor DNA (ctDNA) as a marker for disease recurrence and treatment response.

NCT Number	NCT07318051
Lead Sponsor	Natera, Inc.
Conditions	Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer, Pancreatic Cancer, Ovarian Cancer, Gastroesophageal Cancer, Prostate Cancer +4 more
Enrollment	9,600 participants
Start Date	2025-07-21
Primary Completion	2035-01 (estimated)
Study Completion	2035-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-15